Twenty-one patients showed FDG hypometabolism; the remaining 3 did not. 1 key finding →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
Twenty-one patients showed FDG hypometabolism; the remaining 3 did not. 1 key finding →
Participants: 24 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Language impairment is an important biomarker of neurodegenerative disorders such as Alzheimer's disease (AD). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Subtle and spatially complex deformation patterns of hippocampus between patients with AD and healthy control subjects can be detected by machine learning methods. 2 key findings →
Participants: 19 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Emerging digital tools have the potential to enable a new generation of qualitative and quantitative assessment of cognitive performance. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Language batteries used to assess the skills of elderly individuals, such as naming and semantic verbal fluency, present some limitations in differentiating healthy controls from patients with amnestic mild cognitive impairment (a-MCI). 1 key finding →
Participants: 77 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Mild cognitive impairment (MCI) can be an indicator representing the early stage of Alzheimier's disease (AD). 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
This technique could be applied to questions in social gerontology related to how social media outlets reflect and shape attitudes bearing on other developmental outcomes. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
With the suggested adaptations, the CDN is expected to be a useful tool for supporting community-dwelling persons with mild dementia and their carers. 1 key finding →
Participants: 12 Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
The global population is expected to have about 131.5 million people living with Alzheimer's disease (AD) and other dementias by 2050, posing a severe health crisis. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Down syndrome is the most common genetic developmental disorder in humans and is caused by partial or complete triplication of human chromosome 21 (trisomy 21). 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The pattern of cerebral degeneration in Alzheimer's disease (AD) patients suggests that basic auditory capacities should be normal in AD, whereas progressively higher levels of auditory function should be increasingly impaired. 4 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
It is a piece of evidence that cognitive dysfunction, even in early stage of memory decline, may have some bad impact on balance and gait regardless of the effect of musculoskeletal problems. 5 key findings →
Design: post-hoc analysis Evidence: low
Full summary, score breakdown and related studies → Original source Full text may need a subscription
All groups showed a worsening of cognitive (39.6%), pre-existing (37.5%), and new (26%) behavioral symptoms, and motor symptoms (35.4%) during the COVID-19 lockdown, resulting in an increased caregiver burden in 26% of cases. 5 key findings →
Participants: 34 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The observed misalignment of opinion between end users and developers on desirable design features of companion robots demonstrates the need for user-centred design during development. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Alzheimer's disease and related dementias (ADRD) are highly prevalent conditions, and prior efforts to develop predictive models have relied on demographic and clinical risk factors using traditional logistical regression methods. 5 key findings →
Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Comprehension deficits are common in stroke aphasia, including in cases with (i) semantic aphasia, characterized by poor executive control of semantic processing across verbal and non-verbal modalities; and (ii) Wernicke's aphasia, associated with poor auditory-verbal comprehension and repetition, plus fluent speech with jargon. 2 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Language performance deficits can appear early before impairment in episodic memory, visuospatial construction ability, or mental status in individuals at risk for MCI. 5 key findings →
Participants: 86 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Cortical thickness from MRI helped predict conversion from mild cognitive impairment to dementia in Parkinson disease at an individual level, with improved performance when integrated with clinical variables. © RSNA, 2021 Online supplemental material is available for this article. 2 key findings →
Participants: 75 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Occupational noise exposure accounts for approximately 16% of all disabling hearing losses, but the true value and societal costs may be grossly underestimated because current regulations only identify hearing impairments in the workplace if exposures result in audiometric threshold shifts within a limited frequency region. 3 key findings →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Despite the extended study duration, participants demonstrated high compliance with the schedule of daily learning tasks and were extremely positive about their experiences. 2 key findings →
Participants: 20 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
These data suggest that current treatment of late stage parkinsonism in the community remains insufficiently effective to alleviate disabling symptoms in many patients. 3 key findings →
Participants: 692 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The experimental results demonstrate that the SVM with RBF achieved an encouraging performance with sensitivity (SEN), specificity (SPE), and accuracy (ACC) values of 82.65%, 87.17%, and 84.35%, respectively (AUC = 0.861, 95% CI = 0.820-0.902), for the differential diagnosis between VaD and AD. 2 key findings →
Participants: 93 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
The findings of this study suggest that predictive modeling could inform patients and clinicians about ASCVD at risk for dementia. 3 key findings →
Participants: 29,561 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Machine learning models consistently outperformed conventional approach. 5 key findings →
Participants: 38,746 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Predictive performance was comparable across algorithms, with R² ranging from 0.201 to 0.361, highest in the MCI_All dataset. 5 key findings →
Design: longitudinal study Participants: 4,958 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →